New Osteoarthritis Drugs Coming Down the Pipeline: A Clinical Trial Review by DelveInsight
26 May 2021
Los Angeles, USA, May 25, 2021 (GLOBE NEWSWIRE) -- New Osteoarthritis Drugs Coming Down the Pipeline: A Clinical Trial Review by DelveInsight
Approximately 80+ key companies are developing Osteoarthritis Drugs. The companies with the Osteoarthritis drug candidates in the most advanced stage include Ampio Pharmaceuticals, Techfields Pharma, Biosplice Therapeutics, Taiwan Liposome Company and Bone Therapeutics.
DelveInsight’s “Osteoarthritis Pipeline Insight” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Osteoarthritis pipeline landscapes. It comprises Osteoarthritis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Osteoarthritis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Osteoarthritis pipeline products.
Some of the key takeaways of the Osteoarthritis Pipeline Report
Get an overview of pipeline landscape @ Osteoarthritis Clinical Trials Analysis
Osteoarthritis is a type of arthritis caused by inflammation, breakdown, and eventual loss of cartilage in the joints. Osteoarthritis treatment can be broadly classified into reducing modifiable risk factors, intraarticular therapy, physical modalities, alternative therapies, and surgical treatments.
Osteoarthritis Emerging Drugs
Research and Development
Phase III
NCT03081806: Techfields Pharma, in April 2021, initiated “A Phase 3, Multicenter, 22-Week, Double-Blind and 30-Week Open Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Knee”. This is a Phase 3, Multicenter, 22-Week, double-blind, and 30-Week open-label Study to Evaluate the Efficacy and Safety of X0002 Spray in relief of the signs and symptoms of subjects with Osteoarthritis of the Knee.
Results
Techfields announced excellent results from the Phase II trial of X0002 in China. X0002 is a new anti-inflammatory drug that demonstrated an excellent safety profile and efficacy.
Research and Development
Phase III
NCT03988023: Ampio Pharmaceuticals, in June 2019, initiated “ A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults With Pain Due to Severe Osteoarthritis of the Knee”. The purpose of this study is to confirm the safety and efficacy of Ampion for the treatment of pain and function in patients with severe osteoarthritis of the knee. This study is a randomized, double-blind, single-dose design. This study is conducted on male and female patients between ≥40 and 85 years of age with severe osteoarthritis of the knee. Approximately 1034 patients with severe osteoarthritis of the knee randomized 1 to 1 treatment group (1:1) will receive a single intra- injection of 4 millilitre (mL) of Ampion or saline.
Results
Ampio Pharmaceuticals has reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p < 0.001).
For further information, refer to the detailed report @ Osteoarthritis Pipeline Therapeutics
Scope of Osteoarthritis Pipeline Drug Insight
Key Questions regarding Current Osteoarthritis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.